GENE THERAPY Inactivation by Christopher A. Klug Samuel Cheshier
GENE THERAPY
Inactivation of a GFPretrovirus occurs at multiple levels in long-term
repopulating stem cells and their differentiated progeny
ChristopherA. Klug, Samuel Cheshier, and Irving L. Weissman
Hematopoietic stem cell gene therapy
holds promise for the treatment of many
hematologic disorders. One major vari-
able that has limited the overall success
of gene therapy to date is the lack of
sustained gene expression from viral
vectors in transduced stem cell popula-
tions. To understand the basis for re-
duced gene expression at a single-cell
level, we have used a murine retroviral
vector, MFG, that expresses the green
ﬂuorescent protein (GFP) to transduce
puriﬁed populations of long-term self-
renewing hematopoietic stem cells (LT-
HSC) isolated using the ﬂuorescence-
activated cell sorter. Limiting dilution
reconstitution of lethally irradiated recipi-
ent mice with 100% transduced, GFP1
LT-HSC showed that silencing of gene
expression occurred rapidly in most inte-
gration events at the LT-HSC level, irre-
spective of the initial levels of GFP
expression. When inactivation occurred
at the LT-HSC level, there was no GFP
expression in any hematopoietic lineage
clonally derived from silenced LT-HSC.
Inactivation downstream of LT-HSC that
stably expressed GFP in long-term recon-
stituted animals was restricted primarily
to lymphoid cells. These observations
suggest at least 2 distinct mechanisms of
silencing retrovirally expressed genes in
hematopoietic cells. (Blood. 2000;96:894-
901)
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Introduction
Studies in mice over the last 15 years have shown that pluripoten-
tial hematopoietic stem cells can be transduced with retroviral
vectors, thus establishing the experimental basis for current gene
therapy approaches in humans.1-3 To date, the translation of
experiments done in mice to larger animal models has largely been
unsuccessful, which has highlighted the need for more basic
research in the area of stem cell biology and in the development of
better gene delivery systems.4 The poor success of gene therapy
could be attributed to a number of factors, including the refractory
nature of human stem cells to retroviral transduction,5-7 ineffi-
cient ‘‘seeding’’of cells following adoptive transfer to nonmyeloa-
blated recipients, or the lack of sustained gene expression from
viral vectors.
The long-term maintenance of gene expression following bone
marrow reconstitution has frequently been evaluated in a nonquan-
titative manner. In mice, a number of reports document both the
maintenance8-11 and the lack of sustained gene expression12-14 from
murine retroviral vectors. Complicating the interpretation of these
results are differences in vector design and the cell population
being assayed for expression (day-12 colony-forming units–spleen
cells [CFU-S], in vitro colonies, peripheral blood of reconstituted
animals), the time posttransduction when the assay was performed,
and the means of determining expression (bulk-cell polymerase
chain reaction [PCR], enzymatic assays, or ﬂuorescence-activated
cell sorter [FACS]-selectable markers).Aperceived loss of expres-
sionmayalsohavetodowiththelimitedhalf-lifeofall hematopoietic
progenitors and differentiated progeny that are derived from
long-termself-renewinghematopoieticstemcells(LT-HSC).Trans-
duction of more short-lived multipotential progenitors, typiﬁed by
most day-12 CFU-S–forming cells or transiently reconstituting
multipotent stem cells,15 would be evidenced by sustained expres-
sion for up to about 2 to 3 months, followed by a loss in retrovirus-
positive, short-lived cells.
To address the issue of gene expression from retroviral vectors
in LT-HSC, we have used a murine retrovirus expressing the green
ﬂuorescent protein (MFG-GFP) to transduce a puriﬁed population
of LT-HSC isolated by FACS. The MFG retroviral backbone was
chosen because previous studies showed that MFG-derived vectors
generate high-titer virus and can result in signiﬁcant long termi-
nal repeat (LTR)-driven gene expression in reconstituted ani-
mals.11,16,17TransductionofpuriﬁedLT-HSCfollowedbytransplan-
tation of transduced cells at or near limiting dilution allowed
us to quantitatively determine the percentage of donor stem cells
that sustain retroviral gene expression in the reconstituted animal.
This approach eliminates the ‘‘noise’’ associated with transplanta-
tion of transduced whole bone marrow cells and greatly facilitates
analysis of factors that may inﬂuence gene expression from retro-
viral vectors.
Materials and methods
Generation of retrovirus
MFG-GFP retrovirus was produced by transient transfection of the retrovi-
ral packaging cell line, BOSC 23,18 by calcium phosphate coprecipitation.
BOSC cells were seeded on 6-cm dishes at a density of 2 3 106 cells per
dish the day before transfection. Ten minutes prior to transfection, the
media was changed to Dulbecco’s modiﬁed Eagle’s medium (DMEM)
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894 BLOOD, 1AUGUST 2000 x VOLUME 96, NUMBER 3supplemented with 50-µM chloroquine diphosphate.Atotal of 8 to 10 µg of
DNA was used per transfection. Following the addition of DNA-calcium
phosphate precipitate, plates were incubated for 8 hours in a carbon dioxide
incubator at 37°C, the media were aspirated, and fresh DMEM was gently
added to the dishes. After an additional 16 hours, the media were changed
and the cells were then gently overlaid with a minimal amount of media (2
mL) to collect virus. Viral supernatant was collected after 24 hours and then
centrifuged at 1200 rpm for 5 minutes at 4°C to pellet any packaging cells.
Supernatants were then collected, aliquoted, and frozen. Titering was
done using NIH 3T3 cells seeded on 6-cm dishes at 5 3 105 cells per
dish the day before transduction. Typical titers ranged between 1 3 106
to2 3 106IU/mL.
Isolation of hematopoietic stem cells
Bone marrow cells were obtained by ﬂushing the tibias and femurs with
Hank’s balanced salt solution (Gibco BRL, Grand Island, NY) supple-
mented with 2% donor bovine serum (staining media). Collected cells were
stained with a cocktail of rat monoclonal antibodies to antigens present on
the surface of mature blood cell lineages: 6B2 (anti-B220), M1/70
(anti-Mac-1), 8C5 (anti-Gr-1), Ter-119 (anti-erythrocyte–speciﬁc antigen),
KT31.1 (anti-CD3), 53-7.3 (anti-CD5), GK1.5 (anti-CD4), and 53-6.7
(anti-CD8). Stained cells were washed with staining media and then
incubated with goat antirat phycoerythrin (PE).After washing, free sites on
the antirat antibodies were blocked using normal rat serum or rat
immunoglobulin G (1 µg/mL in phosphate-buffered saline). Stained cells
were washed then incubated with biotinylated E13-161-7 (anti-Sca-1),
ﬂuorescein isothiocyanate–conjugated 19XE5 (anti-Thy-1.1), and allophy-
cocyanin (APC)-conjugated 2B8 (anti-c-kit). Washed cells were then
incubated with streptavidin microbeads (Miltenyi Biotec, Auburn, CA) for
10 minutes, followed by incubation with avidin-Texas Red (Caltag,
Burlingame, CA) for an additional 10 minutes. Sca-11 cells were enriched
by running the sample through a mini-MACS column (Miltenyi Biotec) and
eluting the magnetic fraction according to the manufacturer’s instructions.
All cell sorts were done using a dual laser ﬂow cytometer in the shared
FACS facility at Stanford University. Dead cells were excluded by gating out
propidium-iodide positive cells. The LT-HSC phenotype was sorted as
Sca-11Lin2Thy-1.1loc-kit1.
Hematopoietic stem cell transduction and bone marrow
reconstitution
Sorted stem cells were incubated in 200 µL of DMEM (Gibco BRL, high
glucose) supplemented with 10% fetal calf serum (tested for growth of
embryonic stem cells, Gibco BRL), sodium pyruvate, nonessential amino
acids, and penicillin-streptomycin in a 96-well plate. The media also
contained interleukin-6 (5 ng/mL), Steel factor (50 ng/mL), and 1 3 leuke-
mia inhibitory factor (ESGRO, Gibco BRL). Incubation with cytokines was
carried out for 24 to 28 hours to induce stem cell cycling, after which time
150 µL of the media was removed and replaced with 125 µL of viral
supernatant, 4 µg/mL of polybrene, fresh cytokines, and media to 150 µL.
Infections proceeded for 20 to 24 hours before the cells were washed and
resorted for GFP expression using the FACS. C57BL/J (Ly-5.1, Thy-1.2)
mice were used as recipients for long-term reconstitution assays. Mice were
irradiated with 920 rad given in a split dose separated by 3 hours. Cells were
injected retroorbitally into anesthetized (Metofane) mice that were main-
tained on antibiotics (neomycin sulfate and polymyxin B sulfate) at least 1
month following reconstitution.
PCR of GFP provirus in single cells
Single cells from gated populations were sorted directly into PCR buffer
(supplied by Boehringer Mannheim; ﬁnal concentration: 1.5-mM MgCl2,
50-mM Tris [pH 8.3], 50-mM KCl) supplemented with 0.5% Triton X-100.
Two rounds of nested PCR (30 cycles each) were done using the outside and
inside primer sets listed below. Cycle conditions were 94°C for 1 minute,
55°C for 1 minute, and 72°C for 30 seconds. Five percent of the ﬁrst-round
reaction was used in second-round PCR as template. Ampliﬁed products
were resolved on agarose gels and then blotted for Southern analysis using
an internal, random-primed GFP probe. All primers are written in 58 to 38
orientation. Outside primer set: ATGAGTAAAGGAGAAGAACTTTTC;
ATGGCGTTACTTAAGCTAGC; inside primer set: CTGTCAGTGGAG-
AGGGTGAA; TTTGTATAGTTCATCCATGCC.
Day 8, CFU-S assay
Bone marrow was isolated from primary transplant recipients and then
counted using Tu ¨rk’s solution. A total of 50 000 nucleated cells were
retroorbitally injected into lethally irradiated congenic mice. After 8 days,
spleens were isolated from reconstituted animals, and individual nodules
were microdissected and placed in a proteinase K lysis solution for
overnight digestion. Genomic DNAwas puriﬁed, cut with BamHI, and then
run on a gel for Southern analysis using a random-primed (Pharmacia kit,
Piscataway, NJ) GFP probe that encompassed the entire GFP cDNA (a
unique BamHI site is located just 38 of the GFP coding sequences
in MFG-GFP).
Results
Repopulating potential of LT-HSC transduced with MFG-GFP
retroviral supernatants
In a recent study, we optimized conditions for the transduction of
FACS-sorted, LT-HSC using retroviral supernatants (‘‘Materials
and methods’’; Klug et al, submitted). Retroviral transduction of
FACS-puriﬁed LT-HSC ensures a high multiplicity of infection
(between 10 and 50) and minimizes potentially oncogenic integra-
tion events into more differentiated hematopoietic cells that have
little utility in reconstitution assays. Transduced LT-HSC were
marked by both an allelic marker, Ly-5.2, and the GFP reporter
gene. Inclusion of the GFPgene in the vector allowed us to perform
the repopulation assays using a pure population of transduced cells
that were resorted for GFP expression 20 to 24 hours posttransduc-
tion (Figure 1).
To address whether the in vitro transduction conditions had
altered the functional phenotype of transduced LT-HSC, a limit
dilution dose of transduced (GFP1) cells in reconstitution of
lethally irradiated (Ly-5.11) recipient mice was established. Titra-
tion of input GFP1 stem cells showed that as few as 30 cells were
sufficient to detect donor-derived peripheral blood cells of both
lymphoid and myeloid origin for more than 5 months following
reconstitution (Figure 1). The normal limit dilution dose for
FACS-sorted LT-HSC freshly isolated from bone marrow is
Figure 1. Competitive repopulation assay using GFP1, Ly-5.21 LT-HSC, and
recipient whole bone marrow cells. Increasing numbers of transduced (GFP1),
donor LT-HSC (Ly-5.21) were mixed with 2 3 105 nucleated bone marrow cells of the
recipient type (Ly-5.11). The recipient cells would statistically contain 20 LT-HSC,
only 2 of which would home to bone marrow and contribute to the host-derived
hematopoiesis that is seen in each reconstituted animal. Numbers in the upper right
quadrant of each FACS plot represent the percentage of donor cells in peripheral
blood of the recipient animal.
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dividing HSC reconstitute at lower efficiencies,19,20 which indicates
that there was little loss of LT-HSC activity during the in vitro
transduction procedure. Figure 1 shows data from all reconstituted
animals used in the experiment for 30, 60, and 120 cells.
Signiﬁcantly, at all cell doses tested, there was an almost complete
absence of donor-derived cells that remained GFP1. In an indepen-
dent experiment, 2 of 3 animals were donor-reconstituted with 30
GFP1 cells at 26 weeks, although the percentage of donor
hematopoiesis was only about 1% in the competitive assay (data
not shown). A total of 3 of 3 mice were donor-reconstituted using
60 GFP1 cells, with a mean donor reconstitution of 27%. In all
experiments, the percentage of donor-derived peripheral blood
cells increased with the increase in number of injected donor stem
cells (Figure 1), consistent with data that virtually all LT-HSC
contribute over time to hematopoiesis.21,22 Strikingly, in almost
every case, there was an almost complete absence of Ly-5.21/
GFP1 cells when low numbers of transduced cells were trans-
planted. The limit dilution dose for Ly-5.21/GFP1 cells that
persisted beyond 6 months post-reconstitution was approximately
300 input cells.
The lack of Ly-5.21/GFP1 cells is not due to
deletion of the provirus
To test whether the lack of Ly-5.21/GFP1 peripheral blood cells
was due to loss of the provirus or to silencing of retroviral gene
expression, single-cell PCR was done using cells isolated from
peripheral blood of animals reconstituted for 4 months. Single cells
were sorted from Ly-5.21/GFP1, Ly-5.21/GFP2, and Ly-5.22/
GFP2 populations (Figure 2). Two rounds of PCR were done using
nested primers that hybridize to GFP coding sequences. Products
were resolved on a gel and then blotted for Southern analysis using
an internal GFP probe. Virtually all donor-derived cells contained
at least one copy of an integrated provirus (populations A, B, and
D) whereas host-derived (Ly-5.11) cells (population C) showed no
evidence of a retrovirus even after prolonged exposures of the
Southern blot.Arepeat experiment with an additional reconstituted
mouse showed 9 of 10 positive PCR reactions for both populations
Aand B, respectively, and 0 of 8 positive for population C (data not
shown). In addition, 16 of 16 long-term reconstituted mice were
positive for the presence of an intact provirus based on DNA
Southern blotting of puriﬁed B, T, and myeloid cell populations,
irrespective of the presence of Ly-5.21/GFP1 cells (for example,
see Figure 10 below). This indicates that the lack of GFP
expression in donor-derived peripheral blood cells is due to
transcriptional or translational silencing and that the silencing
mechanism acts at early times post-reconstitution, usually within
the ﬁrst 6 weeks (Figures 1 and 5). Proviral integrants that were not
silenced early continued to express GFP in a signiﬁcant fraction of
Ly-5.21 (donor-derived) peripheral blood cell populations for at
least 6 to 10 months post-reconstitution (Figure 3).This was seen in
13 of 13 animals. There was never evidence of complete inactiva-
tion of expression at later time points in any reconstituted animal.
Secondary bone marrow transfer into irradiated recipient mice
never resulted in reexpression of a silenced GFP reporter gene in a
total of 15 animals examined although, in some cases, silencing of
stably expressing proviruses may have occurred (Figure 4, second-
ary recipients from mouse 9). It remains possible that GFP1 stem
cell clones were not represented at a high enough frequency in the
bone marrow inoculum used for secondary transplantation, so that
apparent ‘‘silencing’’ in secondary recipients was really due to a
lack of reconstitution by GFP1 stem cells. A limit dilution dose of
whole bone marrow cells is approximately 1 3 105 to 2 3 105
cells, which indicates that a signiﬁcant amount of self-renewal had
to have occurred in stem cells that contributed to primary reconsti-
tution of mouse 9.
Silencing is independent of initial levels of GFP expression
We next tested whether sites of retroviral integration that allowed
for high-level GFP expression in LT-HSC might be predictive of
integrants that would be buffered from inactivation. Immediately
following in vitro transduction, cells that expressed low or
extremely high levels of GFP were sorted for reconstitution into
lethally irradiated recipient mice (Figure 5). A total of 350 GFP1
LT-HSC were injected into each reconstituted animal. Peripheral
blood analysis showed that silencing occurred in both groups of
Figure 2. Donor-derived cells in long-term reconstituted animals contain
integrated provirus. Single, Ly-5.21 peripheral blood cells were isolated from
animals reconstituted for 4 months and assayed for the presence of an integrated
provirus using nested PCR. Single cells would predominantly be B, T, and myeloid
cell types, which represent the major, circulating Ly-5.21 cell populations.
Figure 3. Sustained expression of the GFP reporter gene in long-term reconsti-
tuted mice. Peripheral blood of 4 long-term reconstituted animals from 2 indepen-
dent experiments was assayed at the indicated time points for the persistence of GFP
expression over 5 to 6 months. A total of 13 of 13 animals showed sus-
tained long-term expression with little change in the percentage of GFP-expressing
cells. The number of transplanted, GFP1 donor cells per animal are indicated. All
donor cells were mixed with 2 3 105 recipient-type (Ly-5.1) marrow cells prior to
transplantation.
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LT-HSC. Integrants that sustained expression could be found
among animals that received low or high GFP-expressing cells.
GFP expression is silenced in lymphoid progeny that
differentiate from GFP1 LT-HSC
To begin addressing the mechanisms for inactivation of GFP
expression, stem cells were isolated from bone marrow of animals
that had been reconstituted for more than 10 months. In one animal
(L1, the ﬁrst mouse in the GFP/low group from Figure 5), where
the percentage of donor-derived GFP1 cells to donor-derived GFP2
cells (about 50%) was similar in blood and unfractionated bone
marrow, donor-derived stem cells (Ly-5.21Sca-11Lin2c-kit1) were
almost entirely GFP1 (Figure 6).The LT-HSC surface phenotype in
long-term reconstituted primary recipients is similar to that found
in normal (unreconstituted) bone marrow.23 In the absence of
Thy-1.1 staining, this population is approximately 50% pure for
LT-HSC activity. Thy-1.1 staining could not be done because of an
inability to do 6-color analysis with the antibody combination used.
In a second animal (L2, second animal in the low group from
Figure 5), which had a very low percentage of GFP1 cells
remaining in bone marrow 10 months after reconstitution, about
50% of the cells within stem cell gates were GFP1 (Figure 6).
Given that approximately 50% of the cells within these gates are
non-stem cells in the absence of Thy-1.1 staining, there could well
be a similar majority of LT-HSC that remain GFP1 long after the
primary reconstitution.
Southern blot analysis of puriﬁed B cells (B2201 cells from
spleen), myeloid cells (Gr-1 and Mac-11 cells from spleen), and
developing T cells (whole thymus) from mouse L1 showed that
there were 2 independent retroviral integrants that contributed most
of the hematopoiesis seen in the bone marrow and peripheral
lymphoid tissues (Figure 7). To determine whether 2 proviral
integration events occurred in the same stem cell or in 2 indepen-
dent stem cell clones, DNA from day 8 CFU-S was isolated
following secondary transplantation of 50 000 nucleated bone
marrow cells from long-term reconstituted mouse L1. Clonal
analysis indicated that 2 independent stem cell clones (both of
which remained GFP1, Figure 6) were responsible for most of the
hematopoiesis seen in DNA samples isolated from mouse L1 and
that other stem cells were also contributing to hematopoiesis at 10
months post-reconstitution at very low levels (samples 1 and 8).
These rare clones can be seen in longer exposures of the Southern
blot in the B, T, and myeloid cell lanes (data not shown).
Even though the 2 major stem cell clones have remained GFP1
(Figure 6), a signiﬁcant percentage (31.6%) of donor-derived
hematopoiesis is GFP2 within the bone marrow of mouse L1. This
suggests that silencing occurs early in the development of cell
lineages that mature in bone marrow, which would primarily be
erythrocytes, progenitor B cells, and myeloid cells. FACS analysis
of donor-derived cells within bone marrow of mouse L1 (Figure 8)
shows that no inactivation occurred as LT-HSC differentiated into
cells of the erythroid (Ter-119) or myeloid lineages (Mac-1 or
Gr-1). Inactivation was only seen in progenitor B cells (B2201), T
cells (CD31), and natural killer cells (NK-1.11). Notably, a small
percentage of each of these populations remained GFP1. The data
suggest that silencing can occur at a very early stage in lymphoid
cell development, perhaps before the acquisition of B220 surface
expression on progenitor B cells.Although we have no data for the
Figure 4. Expression patterns seen in primary transplant recipients are
generally maintained in long-term reconstituted secondary transplant recipi-
ents. Increasing numbers of whole bone marrow cells from long-term reconstituted
primary recipient mice were transplanted into lethally irradiated secondary recipients
of the Ly-5.1 genotype. Peripheral blood was analyzed from 3 animals representing
mouse 7/11 and 5 animals from mouse 9.
Figure 5. Maintenance of gene expression is not
predictable based on initial levels of GFP expression.
Recipient animals were reconstituted with 350 GFP1,
LT-HSC that initially expressed either low (2 animals) or
high levels (3 animals) of GFP 24 hours after stem cell
transduction.Peripheralbloodwasanalyzedat3.5weeks
and 11.5 weeks post-reconstitution.
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L2, there was clearly a large change in the ratio of GFP1 to GFP2
cells within stem cell gates (Figure 6) versus whole bone marrow.
This difference within bone marrow of mouse L2 indicates that
inactivation can also occur as LT-HSC differentiate into myeloid
cells, although it appears to be much less frequent than inactivation
inlymphoidcells.Analysisofanotherindependentanimalreconsti-
tuted with 300 GFP1 LT-HSC for 6.5 months showed a very similar
GFP expression pattern in the peripheral blood cell lineages
(compare GFP expression in myeloid and lymphoid cells at 26
weeks, Figure 9). The molarity of the Southern blot bands indicates
that at least 4 to 5 independent stem cell clones were contributing
all of the hematopoiesis in the animal. This animal was nearly
100% GFP1 in the myeloid lineages, yet showed signiﬁcant
inactivation in peripheral B- and T-cell populations. This is in
agreement with in vitro data showing that single GFP1 LT-HSC
sorted into 7-factor methylcellulose culture conditions favoring
myeloid cell development do not inactivate GFP expression over
the 10-day time of culture (Samuel Cheshier and Irving L.
Weissman, data not shown).
Silencing can occur at the level of the LT-HSC
The previous observations show that inactivation of retroviral-
mediated gene expression can occur as LT-HSC commit to
differentiate along lymphoid cell pathways in vivo. However, a
very signiﬁcant number of all proviral integration events that
initially express GFP (which permits resorting of cells following
retroviral transduction) go on to inactivate expression from the
integrated provirus (Figure 1). To assess whether LT-HSC re-
mained GFP1 in animals with no sustained GFP expression in
peripheral blood, we analyzed stem cells in a GFP2, long-term
Figure 6. LT-HSC remain GFP1 in signiﬁcantly higher proportion than develop-
ing bone marrow cells. Two mice reconstituted for 10 months were analyzed for
GFP expression in developing bone marrow cells and within the hematopoietic stem
cell population using 5-color FACS analysis. Cells were stained for the donor marker
(Ly-5.2, allophycocyanin), lineage markers (Cy5-PE), c-kit (PE), Sca-1 (Texas Red),
and GFP (ﬂuorescence in the ﬂuorescein isothiocyanate channel). The numbers in
parentheses indicate gating of lineage-marker negative-to-low cells according to the
numeric scale given on the top of the lineage-marker histogram. Donor-derived,
LT-HSC will be present at high purity in the Ly-5.21, Sca-11, c-kit1, Lin (0-80) gated
population. The entire hematopoietic stem cell pool, which includes short-term
reconstituting stem cells, will be present in the Lin (0-100) fraction.
Figure 7. Two independent LT-HSC clones contribute most of the hematopoi-
esis seen in mouse L1. Aportion of the bone marrow used for FACS analysis shown
in Figure 6 was used to inject secondary lethally irradiated mice for day-8 CFU-S. A
total of 50 000 nucleated bone marrow cells were used per injection. Macroscopic
spleen colonies were individually dissected 8 days post-reconstitution, and then
genomic DNAisolated from each colony was used in Southern analysis to determine
each proviral integration site. Whole B, T, and myeloid cell samples were obtained by
positive magnetic bead selection (Miltenyi Biotech) using single cell suspensions of
spleen (B and myeloid cells) and thymus (T cells).
Figure 8. Inactivation of GFP expression occurs primarily as stem cells
differentiate into lymphoid cell populations. Bone marrow cells were stained with
antibodies directed against markers that deﬁne speciﬁc blood cell lineages, including
B cells (B220), monocytes and neutrophils (Mac-1 and Gr-1), primitive erythrocytes
(Ter-119), natural killer cells (NK-1.1), and T cells (CD3). Contour plots showing
mature lineage marker expression are gated for all donor-derived (Ly-5.2) cells.
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10). Even though 46% of bone marrow was donor-derived, no
GFP1 LT-HSC was detected in bone marrow. Based on Southern
blot analysis, one major stem cell clone was contributing almost all
of the donor blood cells in the primary transplant recipient (Figure
11). This indicates that inactivation occurring at the LT-HSC level
is maintained in myeloid cell progeny that normally have the
potential to express genes from the MFG vector (Figures 8 and 9).
Discussion
The studies reported here illustrate at least 2 levels of control that
determine the active state of gene expression from the MFG
retroviral vector in hematopoietic cells. Transplantation of limited
numbers of transduced GFP1 stem cells shows that most retroviral
integrantsaresilencedwithintheﬁrst6weeksfollowingreconstitu-
tion (Figure 1). Silencing at the LT-HSC level may be much more
rapid than 6 weeks due to the half-life of differentiated cells that are
initially GFP1 following reconstitution. Proviral integrants that are
completely silenced cease to express GFP at the LT-HSC level
(Figure 10) and do not show evidence of GFP reexpression upon
differentiation or upon transplantation into secondary irradiated
recipient animals (Figure 4).
Others have demonstrated that a mechanism for retroviral
inactivation could involve de novo methylation of viral sequences
leading to stable propagation of the inactive state.12,24-27 Silencing
of virally expressed genes has been observed in primary ﬁbro-
blasts28,29 and in cultured cell lines.26,30 This points out that
inactivation does not have to correlate with differentiation but,
rather, may be a consequence of stochastic processes inﬂuenced by
DNA replication. This could explain why some integrants, which
were stably expressing GFP in long-term reconstituted primary
recipients, were silenced upon secondary transfer (Figure 4). In the
context of a reconstitution, presumably all stem cells would be
stimulated to cycle rapidly in response to the hematopoietic needs
of the animal. Understanding how chromatin conformation is
reestablished following replication may shed light on why certain
proviral integrants would remain active over successive rounds of
replication while others are silenced. Silencing may occur more
slowly in LT-HSC in primary transplant recipients because of the
slower rate at which this population of cells is cycling in vivo.21,22
The second level of gene inactivation occurs downstream of
LT-HSC and probably involves at least 2 mechanisms. In all
primary transplant recipients that continued to express GFP 8 to 10
weeks after reconstitution (a total of 13 animals), expression
remained stable for long periods. LT-HSC in these animals had a
much higher ratio of GFP1 to GFP2 cells than seen in whole bone
marrow (Figure 6), with the most silencing occurring as LT-HSC
differentiate into lymphoid cells (Figure 8). The early stage at
which silencing was evident in progenitor B cells might suggest
thatsilencingoccursaspartofchromatinremodelingthataccompa-
nies lymphoid cell (or B cell) commitment. Assuming that retrovi-
ruses integrate into ‘‘open’’ chromatin present in hematopoietic
stem cells,31-34 one consequence of differentiation along the
lymphoid cell pathway might be the shutdown of open chromatin
around stem cell genes and the emergence of new open chromatin
domains that mark the unique set of genes deﬁning a particular
lymphoid cell type. Such a mechanism of inactivation would not be
biased toward retroviruses but, rather, would affect all DNA that
preferentially integrates into particular regions of open chromatin.
The involvement of chromatin structure in silencing is strongly
suggested by experiments that showed that completely silenced
genes expressed from an adeno-associated viral backbone could be
fully reactivated using chemical inhibitors of histone deacety-
lases.30 Deacetylation of histones H3 and H4 is associated with the
condensed, transcriptionally inactive state of chromatin.35
Another explanation for the lack of retroviral gene expression in
most lymphoid cells could be the absence of positively acting
transcription factors, or the presence of silencing factors, that
control expression from the retroviral LTR. This is apparently the
case for peripheral T lymphocytes, where only a few percent of
GFP1 cells were also CD31 in all animals tested, as has been in
cases reported for human T cells.36-38 It is unlikely that this
explanation is true for developing B lymphocytes in bone marrow
or in the periphery in that some animals showed at least 50%
positive B-lineage cells at early time points following reconstitu-
tion. This indicates that a high percentage of B cells have the
potential for expressing a gene from the retroviral promoter.
Another possibility is that lymphoid cell populations may express
higher levels of de novo methylase activity than myeloid cells and
are therefore more sensitive to silencing by a methylation-
dependent mechanism.
Our observations are in agreement with a number of studies that
document stable expression of retrovirally driven genes in myeloid
cell populations such as day-12 CFU-S or peripheral blood
monocytes and neutrophils.10,12,13 In some cases, we suspect that
A
B
Figure 9. GFP expression is largely maintained during myeloid differentiation
from stem cells. T, myeloid, and B cells were isolated from the bone marrow and
spleen of a mouse reconstituted for 26 weeks using positive selection with magnetic
beads. The molarity of the Southern bands indicates that at least 5 independent stem
cell clones contribute most of the hematopoiesis in the animal (arrows a-e).The purity
of column-enriched cells was generally 80% to 95% based on reanalysis of enriched
cells. Nearly all donor-derived myeloid cells (monocytes and neutrophils) were GFP1
in the long-term reconstituted animal.
BLOOD, 1AUGUST 2000 x VOLUME 96, NUMBER 3 INACTIVATION OFAGFP RETROVIRUS IN STEM CELLS 899silencing would not be as readily observed in experiments done by
coculturing stem cells with retroviral producer cells (which histori-
cally has been the most commonly used transduction approach)
because of a higher number of integration events per stem cell.
Multiple integrants would mask the actual frequency of silencing
that we observe using a viral supernatant transduction protocol that,
in general, leads to single integration events (13 of 15 single
integrations based on clonal analyses). Although silencing at the
LT-HSC level might be overcome through means that promote
multiple integration events per cell, this has the disadvantage of
increased potential for oncogenic integration events in long-lived
cellsthatcouldaccumulateadditionalmutationsovertime.Improve-
ments in vector design, like murine stem cell virus (MSCV)39 and
MND,40 may overcome the inactivation mechanism operating at
the LT-HSC level that is independent of differentiation status.
These vectors seem promising based on a number of recent
studies,41-44 although the number of proviral integrants per cell
were not evaluated at a clonal level. In one study,44 there were an
estimated 2.5 proviral copies (using MSCV) per haploid genome
based on Southern analysis of hematopoietic tissues from trans-
planted animals. If silencing did occur at frequencies of less than
50% of all integration events, this would be masked by the amount
Figure 10. Silencing occurs at the LT-HSC level.
LT-HSC were analyzed in an animal that showed no
evidence of sustained GFP expression after long-term
reconstitution even though the animal was highly donor-
reconstituted. Donor hematopoietic stem cells were ana-
lyzed for being Ly-5.21 (APC), Sca-11 (Texas Red),
lineagemarker–negative(Cy5-PE),c-kit1(PE),andGFP1
or GFP2.
Figure 11. Donor (Ly-5.21) bone marrow cells contain integrated provirus based
on Southern analysis. Clonal assays to determine the number of proviral integrants
per cell were done on isolated day 8 CFU-S colonies and from single stem cells
FACS-sorted onto a stromal feeder layer (AC-6) that supports cell growth and
expansion so that sufficient amounts of DNA could be isolated for analysis. B, T, and
myeloid cell populations were puriﬁed by magnetic bead enrichment as described
previously. The Southern blot was probed with a randomly primed GFP fragment.
900 KLUG et al BLOOD, 1AUGUST 2000 x VOLUME 96, NUMBER 3of provirus in each cell. Silencing at a very early stage in the
development of lymphoid cells points out the need for further
experiments to understand the nature of the inactivation process in
this arm of the hematopoietic system. Vectors may need to have
modiﬁcations designed to buffer integrated genes from chromatin
effects or vectors that have modiﬁed LTR sequences that are
permissive for expression in lymphoid cells.This will be critical for
targeting a host of lymphoid deﬁciencies. Our preliminary experi-
ments suggest that erythroid cell progenitors that express the
Ter-119 antigen will behave similar to myeloid cells with respect to
retrovirally mediated gene expression (Figure 8). Experiments
addressing sustained gene expression in megakaryocytes and in
dendritic cell populations have not yet been done.
Acknowledgments
We express our appreciation to Libuse Jerabek for laboratory
management, Veronica Braunstein for antibody preparation, Tim
Knaak for FACS operation, and Lucino Hidalgo for animal care.
We also thank Michael Anderson and members of the Weissman
laboratory for helpful and stimulating discussion.
References
1. Havenga M, Hoogerbrugge P, Valerio D, van Es
HH. Retroviral stem cell gene therapy. Stem
Cells. 1997;15:162-179.
2. Mulligan RC. The basic science of gene therapy.
Science. 1993;260:926-932.
3. MillerAD. Human gene therapy comes of age.
Nature. 1992;357:455-460.
4. Orkin SH, MotulskyAG. Report and recommen-
dations of the panel to assess the NIH investment
in research on gene therapy. Bethesda, MD: NIH;
1995.
5. Brenner MK, Rill DR, Holladay MS, et al. Gene
marking to determine whether autologous mar-
row infusion restores long-term haemopoiesis in
cancer patients. Lancet. 1993;342:1134-1137.
6. Dunbar CE, Cottler-Fox M, O’Shaughnessy JA, et
al. Retrovirally marked CD34-enriched peripheral
blood and bone marrow cells contribute to long-
term engraftment after autologous transplanta-
tion. Blood. 1995;85:3048-3057.
7. Kohn DB, Bauer G, Rice CR, et al.Aclinical trial
of retroviral-mediated transfer of a rev-responsive
element decoy gene into CD341 cells from the
bone marrow of human immunodeﬁciency virus-1-
infected children. Blood. 1999;94:368-371.
8. Bender MA, Gelinas RE, MillerAD.Amajority of mice
show long-term expression of a human b-globin
gene after retrovirus transfer into hematopoietic stem
cells. Mol Cell Biol. 1989;9:1426-1434.
9. Einerhand MPW, Bakx TA, KuklerA, Valerio D.
Factors affecting the transduction of pluripotent
hematopoietic stem cells: long-term expression of
a human adenosine deaminase gene in mice.
Blood. 1993;81:254-263.
10. Correll PH, Colilla S, Dave HPG, Karlsson S.
High levels of human glucocerebrosidase activity
in macrophages of long-term reconstituted mice
after retroviral infection of hematopoietic stem
cells. Blood. 1992;80:331-336.
11. Ohashi T, Boggs S, Robbins P, et al. Efficient
transfer and sustained high expression of the hu-
man glucocerebrosidase gene in mice and their
functional macrophages following transplantation
of bone marrow transduced by a retroviral vector.
Proc NatlAcad Sci U SA. 1992;89:11332-11336.
12. Challita P, Kohn DB. Lack of expression from a
retroviral vector after transduction of murine he-
matopoietic stem cells is associated with methyl-
ation in vivo. Proc NatlAcad Sci U SA. 1994;91:
2567-2571.
13. Pawliuk R, Kay R, Lansdorp P, Humphries RK.
Selection of retrovirally transduced hematopoietic
cells using CD24 as a marker of gene transfer.
Blood. 1994;84:2868-2877.
14. Tumas DB, Spangrude GJ, Brooks DM, Williams
CD, Chesebro B. High-frequency cell surface ex-
pression of a foreign protein in murine hematopoi-
etic stem cells using a new retroviral vector.
Blood. 1996;87:509-517.
15. Morrison SJ, Weissman IL. The long-term re-
populating subset of hematopoietic stem cells is
deterministic and isolatable by phenotype. Immu-
nity. 1994;1:661-673.
16. Dranoff G, Jaffee E, LazenbyA, et al. Vaccination
with irradiated tumor cells engineered to secrete
murine granulocyte-macrophage colony-stimulat-
ing factor stimulates potent, speciﬁc, and long-
lasting anti-tumor immunity. Proc NatlAcad Sci
U SA. 1993;90:3539-3543.
17. Riviere I, Brose K, Mulligan RC. Effects of retrovi-
ral vector design on expression of human adeno-
sine deaminase in murine bone marrow trans-
plant recipients engrafted with genetically
modiﬁed cells. Proc NatlAcad Sci U SA. 1995;
92:6733-6737.
18. Pear WS, Nolan GP, Scott ML, Baltimore D. Pro-
duction of high-titer helper-free retroviruses by
transient transfection. Proc NatlAcad Sci U SA.
1993;90:8392-8396.
19. Fleming WH,Alpern EJ, Uchida N, Ikuta K, Span-
grude GJ, Weissman IL. Functional heterogeneity
is associated with the cell cycle status of murine
hematopoietic stem cells. J Cell Biol. 1993;122:
897-902.
20. Habibian HK, Peters SO, Hsieh CC, et al. The
ﬂuctuating phenotype of the lymphohematopoi-
etic stem cell with cell cycle transit. J Exp Med.
1998;188:393-398.
21. Bradford GB, Williams B, Rossi R, Bertoncello I.
Quiescence, cycling, and turnover in the primitive
hematopoietic stem cell compartment. Exp He-
matol. 1997;25:445-453.
22. Cheshier SH, Morrison SJ, Liao X, Weissman IL.
In vivo proliferation and cell cycle kinetics of long-
term self-renewing hematopoietic stem cells.
Proc NatlAcad Sci U SA. 1999;96:3120-3125.
23. Morrison SJ, WandyczAM, Hemmati HD, Wright
DE, Weissman IL. Identiﬁcation of a lineage of
multipotent hematopoietic progenitors. Develop-
ment. 1997;124:1929-1939.
24. Stewart CL, Stuhlmann H, Jahner D, Jaenisch R.
De novo methylation, expression, and infectivity
of retroviral genomes introduced into embryonal
carcinoma cells. Proc NatlAcad Sci U SA. 1982;
79:4098-4102.
25. Jahner D, Stuhlmann H, Stewart CL, et al. De
novo methylation and expression of retroviral ge-
nomes during mouse embryogenesis. Nature.
1982;298:623-628.
26. Hoeben RC, MigchielsenAAJ, van der Jagt RCM,
van Ormondt H, van der EbAJ. Inactivation of the
Moloney murine leukemia virus long terminal re-
peat in murine ﬁbroblast cell lines is associated
with methylation and dependent on its chromo-
somal position. J Virol. 1991;65:904-912.
27. Yoder JA, Walsh CP, Bestor TH. Cytosine methyl-
ation and the ecology of intragenomic parasites.
Trends Genet. 1997;13:335-340.
28. Dwarki VJ, Belloni P, Nijjar T, et al. Gene therapy
for hemophiliaA: production of therapeutic levels
of human factor VIII in vivo in mice. Proc Natl
Acad Sci U SA. 1995;92:1023-1027.
29. Palmer TD, Rosman GJ, Osborne WRA, Miller
AD. Genetically modiﬁed skin ﬁbroblasts persist
long after transplantation but gradually inactivate
introduced genes. Proc NatlAcad Sci U SA.
1991;88:1330-1334.
30. Chen WY, Bailey EC, McCune SL, Dong J-Y,
Townes TM. Reactivation of silenced, virally
transduced genes by inhibitors of histone
deacetylase. Proc NatlAcad Sci U SA. 1997;94:
5798-5803.
31. Vijaya S, Steffen DL, Robinson HL.Acceptor sites
for retroviral integration map near DNase I-hyper-
sensitive sites in chromatin. J Virol. 1986;60:683-
692.
32. Rohdewohld H, Weiher W, Reik R, Jaenisch R,
Breindl M. Retrovirus integration and chromatin
structure: Moloney murine leukemia virus integra-
tion sites map near DNase I-hypersensitive sites.
J Virol. 1987;63:336-343.
33. Scherdin U, Rhodes K, Breindl M. Transcription-
ally active genome regions are preferred integra-
tion sites for retrovirus integration. J Virol. 1990;
64:907-912.
34. Mooslehner K, Karls U, Harbers K. Retroviral in-
tegration sites in transgenic Mov mice frequently
map in the vicinity of transcribed DNAregions.
J Virol. 1990;64:3056-3058.
35. Grunstein M. Histone acetylation in chromatin
structure and transcription. Nature. 1997;389:
349-352.
36. Plavec I,Agarwal M, Ho KE, et al. High trans-
dominant RevM10 protein levels are required to
inhibit replication in cell lines and primary T cells:
implication for gene therapy ofAIDS. Gene Ther.
1997;4:128-139.
37. Quinn ER, Lum LG, Trevor KT. T cell activation
modulates retrovirus-mediated gene expression.
Hum Gene Ther. 1998;9:1457-1467.
38. Kohn DB, Hershﬁeld MS, Carbonaro D, et al. T
lymphocytes with a normalADAgene accumulate
after transplantation of transduced autologous
umbilical cord blood CD341 cells in ADA-deﬁ-
cient SCID neonates. Nat Med. 1998;4:775-780.
39. Hawley RG, Lieu FHL, FongAZC, Hawley TS.
Versatile retroviral vectors for potential use in
gene therapy. Gene Ther. 1994;1:136-138.
40. Robbins PB, Yu X-J, Skelton DM, et al. Increased
probability of expression from modiﬁed retroviral
vectors in embryonal stem cells and embryonal
carcinoma cells. J Virol. 1997;71:9466-9474.
41. Cheng L, Du C, Lavau C, et al. Sustained gene
expression in retrovirally transduced, engrafting
human hematopoietic stem cells and their lym-
pho-myeloid progeny. Blood. 1998;92:83-92.
42. Robbins PB, Skelton DC, Yu XJ, Halene S, Leo-
nard EH, Kohn DB. Consistent, persistent expres-
sion from modiﬁed retroviral vectors in murine
hematopoietic stem cells. Proc NatlAcad Sci
U SA. 1998;95:10182-10187.
43. Persons DA,Allay JA, Riberdy JM, et al. Use of
the green ﬂuorescent protein as a marker to iden-
tify and track genetically modiﬁed hematopoietic
cells. Nat Med. 1998;4:1201-1204.
44. Pawliuk R, Eaves CJ, Humphries RK. Sustained
high-level reconstitution of the hematopoietic sys-
tem by preselected hematopoietic cells express-
ing a transduced cell-surface antigen. Hum Gene
Ther. 1997;8:1595-1604.
BLOOD, 1AUGUST 2000 x VOLUME 96, NUMBER 3 INACTIVATION OFAGFP RETROVIRUS IN STEM CELLS 901